First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform [Yahoo! Finance]
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Cabaletta Bio (CABA) had its price target lowered by Morgan Stanley from $14.00 to $13.00. They now have an "overweight" rating on the stock.
Cabaletta Bio (CABA) had its price target raised by Guggenheim from $15.00 to $16.00. They now have a "buy" rating on the stock.